Tag: Medtronic

Results Announced from Two Renal Denervation Studies at EuroPCR Show Positive Outcomes in High-Risk Hypertensive Patients

DUBLIN and PARIS – May 22, 2019 – Investigators today unveiled late-breaking clinical data from a first-of-its-kind physician sponsored clinical trial. The data indicate that renal denervation (RDN) with the Medtronic Symplicity(TM) renal denervation system was associated with reduced occurrence of subclinical atrial fibrillation (AF) in a small subset of high-risk […]

Medtronic Launches Telescope(TM) Guide Extension Catheter to Support Complex Coronary Cases

DUBLIN – May 16, 2019 – Medtronic plc (NYSE:MDT), a global leader in percutaneous coronary intervention (PCI) innovation, today announced its entrance into the guide extension catheter market with the global launch of the Telescope(TM) Guide Extension Catheter, a newly designed catheter used to provide additional backup support and access to […]

Philips announces collaboration with Medtronic to further advance the image-guided treatment of atrial fibrillation

May 9, 2019 Philips’ integrated solution will combine the unique KODEX-EPD dielectric imaging and navigation system, dielectric imaging sensors, clinical software, and services to support cryoablation procedures performed with the Medtronic Arctic Front Advance™ cryoablation technology Amsterdam, The Netherlands – Royal Philips (NYSE: PHG, AEX: PHIA) today announced a collaboration with Medtronic to further advance […]

Medtronic Receives FDA Approval for CareLink SmartSync Device Manager

DUBLIN – May 2, 2019 – Medtronic plc (NYSE:MDT) today announced that the company has received U.S. Food and Drug Administration (FDA) approval for the CareLink SmartSync(TM) Device Manager. With the introduction of SmartSync, physicians will now be able to use an Apple® iPad® to program and manage data from Medtronic’s BlueSync-enabled […]

Medtronic Receives FDA Approval for World’s First Quadripolar Active Fixation Left Heart Lead

DUBLIN – May 1, 2019 – Medtronic plc (NYSE:MDT) announced it has received U.S. Food and Drug Administration (FDA) approval for the Attain Stability(TM) Quad MRI SureScan(TM) left heart lead. Paired with Medtronic quadripolar cardiac resynchronization therapy-defibrillators (CRT-D) and -pacemakers (CRT-P), the Attain Stability Quad lead is the only active-fixation left […]

Medtronic Announces U.S. Commercial Launch of Solitaire(TM) X Revascularization Device

DUBLIN – April 30, 2019 – Medtronic plc (NYSE:MDT) today announced the U.S. launch of the Solitaire(TM) X Revascularization Device – and its first use in patients for the treatment of acute ischemic stroke. For ten years, the industry-leading Solitaire(TM) Revascularization Device has enabled physicians in helping patients have a better […]

Medtronic HeartWare(TM) HVAD(TM) System Demonstrates Reduction in Total Strokes, Disabling Strokes and Stroke-Related Mortality with Blood Pressure Management

DUBLIN and ORLANDO, Fla. – April 5, 2019 – Medtronic plc (NYSE:MDT) today announced the results of an analysis on the impact of stroke severity in patients receiving its HeartWare(TM) HVAD(TM) System as destination therapy, showing that targeted blood pressure management helped reduce serious strokes. The HVAD System is a left […]

Medtronic Announces the Upsizing of its Maximum Tender Offers for Certain Outstanding Debt Securities Issued by Medtronic, Inc. and Covidien International Finance S.A.

DUBLIN – March 4, 2019 – Medtronic plc (the “Company”) (NYSE:MDT) today announced the upsizing of the previously-announced cash tender offers by its wholly-owned subsidiaries, Medtronic, Inc. and Covidien International Finance S.A. (“CIFSA” and, together with Medtronic, Inc., the “Offerors”) for up to $1.9 billion combined aggregate purchase price (excluding accrued […]

Medtronic Resolute(TM) Drug-Eluting Stent (DES) Platform Receives Expanded Indication for Treatment of Chronic Total Occlusion (CTO)

DUBLIN – February 26, 2019 – Medtronic plc (NYSE:MDT) today announced the U.S. Food and Drug Administration (FDA) approval of its Resolute Drug-Eluting Stent (DES) platform (including the Resolute Onyx(TM) and Resolute Integrity(TM) DES) for the treatment of patients with coronary artery disease who have de novo chronic total occlusion (CTO), a complex […]